Literature DB >> 23859779

Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1.

O Alexander H Strand1, Gulzeb Aziz, Sidra Farzand Ali, Ragnhild E Paulsen, Trond Vidar Hansen, Pål Rongved.   

Abstract

The lipophilic, cell-penetrating zinc chelator N,N,N',N',-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN, 1) and the zinc chelating procaspase-activating compound PAC-1 (2) both have been reported to induce apoptosis in various cell types. The relationship between apoptosis-inducing ability and zinc affinity (Kd), have been investigated with two new model compounds, ZnA-DPA (3) and ZnA-Pyr (4), and compared to that of TPEN and PAC-1. The zinc-chelating o-hydroxybenzylidene moiety in PAC-1 was replaced with a 2,2'-dipicoylamine (DPA) unit (ZnA-DPA, 3) and a 4-pyridoxyl unit (ZnA-Pyr, 4), rendering an order of zinc affinity TPEN>ZnA-Pyr>ZnA-DPA>PAC-1. The compounds were incubated with the rat pheochromocytoma cell line PC12 and cell death was measured in combination with ZnSO4, a caspase-3 inhibitor, or a ROS scavenger. The model compounds ZnA-DPA (3) and ZnA-Pyr (4) induced cell death at higher concentrations as compared to PAC-1 and TPEN, reflecting differences in lipophilicity and thereby cell-penetrating ability. Addition of ZnSO4 reduced cell death induced by ZnA-Pyr (4) more than for ZnA-DPA (3). The ability to induce cell death could be reversed for all compounds using a caspase-3-inhibitor, and most so for TPEN (1) and ZnA-Pyr (4). Reactive oxygen species (ROS), as monitored using dihydro-rhodamine (DHR), were involved in cell death induced by all compounds. These results indicate that the Zn-chelators ZnA-DPA (3) and ZnA-Pyr (4) exercise their apoptosis-inducing effect by mechanisms similar to TPEN (1) and PAC-1 (2), by chelation of zinc, caspase-3 activation, and ROS production.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Apoptosis; CVRXLMUYFMERMJ-UHFFFAOYSA-N; Caspase-3 activation; PAC-1 analogues; QFPVDYVNRNGXRQ-FSJBWODESA-N; ROS production; UBFPFEYJQOUETN-UHFFFAOYSA-N; YQNRVGJCPCNMKT-LFVJCYFKSA-N; Zinc chelators

Mesh:

Substances:

Year:  2013        PMID: 23859779     DOI: 10.1016/j.bmc.2013.06.037

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.

Authors:  Howard S Roth; Rachel C Botham; Steven C Schmid; Timothy M Fan; Levent Dirikolu; Paul J Hergenrother
Journal:  J Med Chem       Date:  2015-04-20       Impact factor: 7.446

2.  Zinc deficiency causes neural tube defects through attenuation of p53 ubiquitylation.

Authors:  Huili Li; Jing Zhang; Lee Niswander
Journal:  Development       Date:  2018-12-13       Impact factor: 6.868

3.  Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.

Authors:  Matthew W Boudreau; Jessie Peh; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2019-07-16       Impact factor: 5.100

4.  Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.

Authors:  Howard S Roth; Paul J Hergenrother
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

5.  Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.

Authors:  Fangyang Wang; Yajing Liu; Lihui Wang; Jingyu Yang; Yanfang Zhao; Nannan Wang; Qi Cao; Ping Gong; Chunfu Wu
Journal:  J Cell Mol Med       Date:  2015-03-08       Impact factor: 5.310

6.  Procaspase-3-activating compound 1 stabilizes hypoxia-inducible factor 1α and induces DNA damage by sequestering ferrous iron.

Authors:  Feifei Li; Aili Wei; Lijuan Bu; Long Long; Wei Chen; Chen Wang; Changqi Zhao; Lili Wang
Journal:  Cell Death Dis       Date:  2018-10-04       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.